The Effects of 4-Aminopyridine on Neurological Deficits in Chronic Cases of Traumatic Spinal Cord Injury in Dogs: A Phase I Clinical Trial

1991 ◽  
Vol 8 (2) ◽  
pp. 103-119 ◽  
Author(s):  
ANDREW R. BLIGHT ◽  
JAMES P. TOOMBS ◽  
MICHAEL S. BAUER ◽  
WILLIAM R. WIDMER
Keyword(s):  
Clinical Trial ◽  
Spinal Cord ◽  
Spinal Cord Injury ◽  
Phase I ◽  
Phase I Clinical Trial ◽  
Neurological Deficits ◽  
Traumatic Spinal Cord Injury ◽  
Cord Injury

Riluzole for the treatment of acute traumatic spinal cord injury: rationale for and design of the NACTN Phase I clinical trial

2012 ◽  
Vol 17 (Suppl1) ◽  
pp. 151-156 ◽  
Author(s):  
Michael G. Fehlings ◽  
Jefferson R. Wilson ◽  
Ralph F. Frankowski ◽  
Elizabeth G. Toups ◽  
Bizhan Aarabi ◽  
...  
Keyword(s):  
Clinical Trial ◽  
Spinal Cord ◽  
Spinal Cord Injury ◽  
Phase I ◽  
Phase I Trial ◽  
Neuronal Degeneration ◽  
Pharmacokinetic Profile ◽  
Traumatic Spinal Cord Injury ◽  
Clinical Trial Registration ◽  
Cord Injury

In the immediate period after traumatic spinal cord injury (SCI) a variety of secondary injury mechanisms combine to gradually expand the initial lesion size, potentially leading to diminished neurological outcomes at long-term follow-up. Riluzole, a benzothiazole drug, which has neuroprotective properties based on sodium channel blockade and mitigation of glutamatergic toxicity, is currently an approved drug that attenuates the extent of neuronal degeneration in patients with amyotrophic lateral sclerosis. Moreover, several preclinical SCI studies have associated riluzole administration with improved functional outcomes and increased neural tissue preservation. Based on these findings, riluzole has attracted considerable interest as a potential neuroprotective drug for the treatment of SCI. Currently, a Phase I trial evaluating the safety and pharmacokinetic profile of riluzole in human SCI patients is being conducted by the North American Clinical Trials Network (NACTN) for Treatment of Spinal Cord Injury. The current review summarizes the existing preclinical and clinical literature on riluzole, provides a detailed description of the Phase I trial, and suggests potential opportunities for future investigation. Clinical trial registration no.: NCT00876889.

scholarly journals A Phase I/IIa Clinical Trial of a Recombinant Rho Protein Antagonist in Acute Spinal Cord Injury

2011 ◽  
Vol 28 (5) ◽  
pp. 787-796 ◽  
Author(s):  
Michael G. Fehlings ◽  
Nicholas Theodore ◽  
James Harrop ◽  
Gilles Maurais ◽  
Charles Kuntz ◽  
...  
Keyword(s):  
Clinical Trial ◽  
Spinal Cord ◽  
Spinal Cord Injury ◽  
Phase I ◽  
Acute Spinal Cord Injury ◽  
Cord Injury ◽  
Rho Protein

scholarly journals Mesenchymal stem cells promote augmented response of endogenous neural stem cells in spinal cord injury of rats

2016 ◽  
Vol 37 (3) ◽  
pp. 1355 ◽  
Author(s):  
Marta Rocha Araujo ◽  
Pablo Herthel Carvalho ◽  
Taís Silva de Paula ◽  
Bárbara Silva Okano ◽  
Ricardo Junqueira Del Carlo ◽  
...  
Keyword(s):  
Spinal Cord ◽  
Stem Cells ◽  
Spinal Cord Injury ◽  
Mesenchymal Stem Cells ◽  
Experimental Models ◽  
Neurological Deficits ◽  
Traumatic Spinal Cord Injury ◽  
Post Injury ◽  
Cord Injury ◽  
Significant Attenuation

Traumatic spinal cord injury results in severe neurological deficits, mostly irreversible. The cell therapy represents a strategy for treatment particularly with the use of stem cells with satisfactory results in several experimental models. The aim of the study was to compare the treatment of spinal cord injury (SCI) with and without mesenchymal stem cells (MSC), to investigate whether MSCs migrate and/or remain at the site of injury, and to analyze the effects of MSCs on inflammation, astrocytic reactivity and activation of endogenous stem cells. Three hours after SCI, animals received bone marrow-derived MSCs (1×107 in 1mL PBS, IV). Animals were euthanized 24 hours, 7 and 21 days post-injury. The MSC were not present in the site of the lesion and the immunofluorescent evaluation showed significant attenuation of inflammatory response with reduction in macrophages labeled with anti-CD68 antibody (ED1), decreased immunoreactivity of astrocytes (GFAP+) and greater activation of endogenous stem cells (nestin+) in the treated groups. Therefore, cell transplantation have a positive effect on recovery from traumatic spinal cord injury possibly due to the potential of MSCs to attenuate the immune response.

P166. The Cethrin Phase I/IIa Prospective Clinical Trial of a Cethrin for the Treatment of Acute Spinal Cord Injury

2007 ◽  
Vol 7 (5) ◽  
pp. 159S ◽  
Author(s):  
Michael Fehlings ◽  
Nicholas Theodore ◽  
James Harrop ◽  
Gilles Maurais ◽  
Charles Kuntz ◽  
...  
Keyword(s):  
Clinical Trial ◽  
Spinal Cord ◽  
Spinal Cord Injury ◽  
Phase I ◽  
Acute Spinal Cord Injury ◽  
Prospective Clinical Trial ◽  
Cord Injury
Sign in / Sign up

Export Citation Format

Share Document